MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
May 06 2024 - 12:00PM
Business Wire
Article 223-16 of the General Regulations of
the Financial Markets Authority (AMF - Autorité des Marchés
Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a
clinical-stage biotechnology company and a leader in the
development of Microbiome Ecosystem Therapies™ (MET) dedicated to
enhancing survival of patients with cancer, today published the
number of shares comprising the share capital and the total number
of voting rights (Article L. 233-8 of the French Commercial Code
(Code de commerce) and Article 223-16 of the General Regulations of
French Autorité des Marchés Financiers (AMF)) on April 30,
2024.
Listing place: Euronext Paris ISIN code:
FR0012634822 Website: www.maatpharma.com
Date
Total number of shares comprising
the share capital
Total number of theoretical
voting rights (1)
Total number of effective voting
rights (2)
04/30/2024
11 623 653
11 623 653
11 602 636
(1) In accordance with Article 223-11 of
the AMF General Regulation, this number is calculated on the basis
of all shares to which voting rights are attached, including shares
whose voting rights have been suspended.
(2) Effective voting rights correspond to
the total number of voting rights that may be used at a General
Meeting. The total number of effective voting rights is calculated
without taking into account the shares with suspended voting
rights.
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has launched, in
March 2022, an open-label, single arm Phase 3 clinical trial in
patients with acute GvHD, following the achievement of its proof of
concept in a Phase 2 trial. Its powerful discovery and analysis
platform, gutPrint®, enables the identification of novel disease
targets, evaluation of drug candidates, and identification of
biomarkers for microbiome-related conditions. The company’s
Microbiome Ecosystem Therapies are produced through a standardized
cGMP manufacturing and quality control process to safely deliver
the full diversity of the microbiome, in liquid and oral
formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice. MaaT Pharma is listed on Euronext
Paris (ticker: MAAT).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240506732977/en/
MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D.
Head of Investor Relations +33 6 16 48 92 50
invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 14 06 45 92
media@maat-pharma.com
Trophic Communications Jacob VERGHESE or Priscillia
PERRIN +49 151 7441 6179 maat@trophic.eu
Maat Pharma (EU:MAAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maat Pharma (EU:MAAT)
Historical Stock Chart
From Jul 2023 to Jul 2024